arterial hypertensionmetoprololартериальная гипертензияметопролол1.Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваскул. тер. и профилак. 2008; (Прил. 2) 7 (6).2.ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.3.Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983-92.4.Williams B, Poulter NR, Brown MJ et al. The BHS Guidelines Working Party Guidelines for Management of Hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18: 139-85.5.Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006; 7 (2): 61-3.6.Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366 (9496): 1545-53.7.Wiysonge CS, Bradley H, Mayosi BM et al. Beta blockers for hypertension. Cochrane Database Review 2007; 1: CD002003.8.Jackson PR, Ramsay LE; United States JNC VI and British Hypertension Society Guideline; International WHO/ISH Guideline. First-line treatment for hypertension. Eur Heart J 2002; 23 (3): 179-82.9.Staessen JA, Wang JG, Birkenh_ger WH. Outcome beyond blood pressure control? Eur Heart J 2003; 24 (6): 504-14.10.Psaty BM, Lumley T et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289 (19): 2534-244.11.Turnbull F, Neal B et al. Blood Pressure Lowering Treatment Trialists\' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165 (12): 1410-9.12.Omvik P, Leer J, Istad H, Westergren G. Equal Efficacy and Improved Tolerability with 50 mg Controlled-Release Metoprolol Compared with 100 mg Conventional Metoprolol in Hypertensive Patients. Am J Ther 1994; 1 (1): 65-73.13.Egstrup et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. J Clin Pharmacol 1988; 33.14.Остроумова О.Д., Рыкова А.М. и др. Выбор антигипертензивных препаратов у больных с сочетанием артериальной гипертензии и ишемической болезни сердца: фокус на b-блокаторы. Consilium Medicum 2007; 9 (5).15.Frishman WH. Postinfarction survival: role of beta-adrenic blocade, in Fuster V (ed): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippencott, 1996; 1205-14.16.Hedblad B, Wikstrand J, Janzon L et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103 (13): 1721-6.17.Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-7.